Bioservo publishes prospectus and invites to investor presentations

The prospectus that Bioservo Technologies AB (publ) ("Bioservo" or the "Company") has prepared in connection with the new share issue of approximately SEK 64.3 million with preferential rights for Bioservo's shareholders (the "Rights Issue") has today been approved by and registered with the Swedish Financial Supervisory Authority ("Finansinspektionen"). Due to the Rights Issue, Bioservo invites to four investor meetings during September.

Prospectus

The prospectus that Bioservo has prepared in connection with the upcoming Rights Issue has today been approved and registered with Finansinspektionen. The prospectus, containing full terms and instructions, as well as a summarizing folder and application forms, can be obtained from Bioservo and Erik Penser Bank and will be kept available on Bioservo’s website (www.bioservo.com) and on Erik Penser Bank's website (www.penser.se). The prospectus will also be available on Finansinspektionen's website (www.fi.se). The summary folder will be sent by mail to Bioservo's direct and nominee registered shareholders in connection with the commencement of the subscription period of the Rights Issue.

Invitation to investor meetings

Due to the Rights Issue, Bioservo will present the Company's operations and future plans on September 17, 2019 at Aktiespararna, Medicon Village, Scheeletorget 1, Lund, on September 18, 2019 at Erik Penser Bank, Apelbergsgatan 27, Stockholm, on September 23, 2019 at Aktiespararna, Svenska Mässan, Mässans gata 18, Göteborg, and on September 25, 2019 at Småbolagsjakten Live, Grev Turegatan 30, Stockholm.

Registration to attend must be submitted to Aktiespararna, through www.aktiespararna.se, to Erik Penser Bank, through seminarium@penser.se, and to Småbolagsjakten, through www.investerarbrevet.se. Please note that the number of seats are limited.

Summary of the Rights Issue

• Shareholders in Bioservo receive one (1) subscription right per share held on the record date, September 12, 2019.
• Five (5) subscription rights entitle to subscription of three (3) new shares in Bioservo.
• The subscription price is SEK 12.00 per share.
• At full subscription, Bioservo will receive approximately SEK 64.3 million before issue costs.
• The Subscription period is September 16 - 30, 2019.
• Trading in subscription rights takes place during the period September 16 – 26, 2019.

The company has received subscription commitments from an existing shareholders of SEK 24.9 million, corresponding to 38.7 percent of the Rights Issue. In addition, the Company has received underwriting guarantees from external investors of SEK 26.5 million, corresponding to 41.3 percent. Total subscription commitments and underwriting guarantees amount to SEK 51.5 million, corresponding to 80.0 percent.

Advisors

Erik Penser Bank AB is financial advisor and Advokatfirman Glimstedt is legal advisor to Bioservo in connection with the Rights Issue.

For further information please contact:

Petter Bäckgren

CEO

petter.backgren@bioservo.com

+46 8 21 17 10

or

Jacob Michlewicz

CFO

jacob.michlewicz@bioservo.com

+46 8 21 17 10

About Bioservo Technologies AB

Bioservo Technologies (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology –wearable non-invasive devices –for people in need of extra power to optimize the body’s endurance and performance, or for people with reduced muscle strength.

Bioservo Technologies AB was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska Hospital. Since its inception, Bioservo Technologies AB has further developed its acclaimed and patented SEM ™ technology (Soft Extra Muscle) and is the world leader in wearable soft robotics.

Bioservo Technologies is dedicated to becoming the world-leading developer of wearable technologies based on bionic soft robotics.

The commitment is based on a true belief that this technology will change the lives for many people, enhancing their independence and quality-of-life. Our innovative solutions are already delivering future business opportunities and breakthrough technologies. We are extremely proud to have been top-ranked for our technological and innovative progress in both Europe and in Sweden. Our revolutionary SEM™ (Soft Extra Muscle) technology was invented by Professor Hans von Holst (neurosurgery), Professor Jan Wikander and Doctor Johan Ingvast, PhD (mechatronic engineering).

FNCA Sweden AB, +46(0)8-52800399, info@fnca.se is the company’s Certified Adviser on Nasdaq First North Growth Market.

For more information, please visit www.bioservo.com

Important information

The information in this press release does not constitute an offer to acquire, subscribe or otherwise trade in shares or other securities issued by Bioservo Technologies AB (publ). Invitation to interested parties to subscribe for shares in Bioservo Technologies AB (publ) will only be made through the prospectus that Bioservo Technologies AB (publ) will publish.

The information in this press release may not be released, published, reproduced or distributed in or to the United States, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa or New Zealand or any other country or jurisdiction where such action is not permitted or where such action is subject to legal restrictions or would require further registration or other measures than what is required by Swedish law. Measures contrary to this instruction may constitute a breach of applicable securities legislation.

No shares have been registered, and will not be registered, in accordance with the United States Securities Act from 1933 (“Securities Act”) and may not be offered, subscribed, sold or transferred, directly or indirectly, within the United States except after written approval from Bioservo Technologies AB (publ) and under an applicable exemption from the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or any other jurisdiction in the United States.